REN and liver dysplastic nodule: Diabetic nephropathy (DN)(1, 2) is a major cause of end‐stage renal disease (ESRD).3, 4 Current therapies for DN entail intensive glycemic control and inhibition of renin‐angiotensin systems,3, 5 but in many cases, these therapies fail to prevent progression to ESRD.6 Consequently, it is important to identify new and plausible therapeutic targets for DN.